ArticleHuman genome variation2026
Carney complex with PRKAR1A variant and breast/fibrolamellar carcinomas.
Article in Human genome variation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carney complex is a rare multiple neoplasia syndrome caused primarily by inactivating variants in the PRKAR1A gene, which encodes the regulatory subunit type I alpha of protein kinase A. Although classically associated with myxomas, lentigines, and endocrine tumors, the full tumor spectrum related to PRKAR1A loss of function is not completely defined. Here, we report a patient with a molecularly confirmed diagnosis of Carney complex carrying a de novo PRKAR1A (NM_002734.5):c.348+1G>A splice-site variant. In addition to typical manifestations, the patient developed two uncommon malignancies: invasive breast carcinoma (luminal B-like) at a young age and fibrolamellar hepatocellular carcinoma lacking the DNAJB1-PRKACA fusion typically found in sporadic cases. The coexistence of these two rare tumors in a single carrier of a pathogenic PRKAR1A variant expands the phenotypic variability associated with this condition and supports the possibility that PRKAR1A loss contributes to oncogenesis beyond the classical endocrine and mesenchymal tissues. This Data Report provides clinically relevant documentation of an unusual tumor presentation associated with a pathogenic PRKAR1A variant and underscores the importance of ongoing clinical surveillance in affected individuals.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.